LGT Fund Management Co Ltd. Has $266,000 Stock Holdings in Insulet Co. (NASDAQ:PODD)

LGT Fund Management Co Ltd. lowered its holdings in Insulet Co. (NASDAQ:PODD) by 22.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,020 shares of the medical instruments supplier’s stock after selling 296 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Insulet were worth $266,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PODD. Baillie Gifford & Co. raised its position in shares of Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after buying an additional 79,982 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of Insulet by 7.6% during the fourth quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock worth $98,605,000 after buying an additional 26,594 shares in the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Raymond James reissued an “outperform” rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $289.06.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Up 0.1 %

PODD stock opened at $272.64 on Tuesday. The firm has a market capitalization of $19.15 billion, a PE ratio of 47.09, a PEG ratio of 3.62 and a beta of 1.23. The business’s 50 day simple moving average is $274.20 and its 200 day simple moving average is $251.26. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, research analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.